Our mission is to develop novel Id-protein targeted small molecule therapeutics in oncology and vascular diseases of the eye the eye.
Background and History of the Company
We are a public bio-pharmaceutical company dedicated to the development and commercialization of a novel, inexpensive treatment for vascular diseases including many forms of cancer and macular degeneration.
AngioGenex was created to capture the full potential of the Id platform. It currently owns unencumbered exclusive world-wide rights under issued and pending patents to a novel class of drugs that target the ID proteins. Central to this strategy is the company’s symbiotic relationship with MSKCC, which includes a coordinated R&D program and clinical trial plan. MSKCC holds common stock in the Company that was granted in return for the efforts it contributed to Dr. Benezra’s early efforts in discovering the role of the ID proteins and their potential as targets for disease intervention.
AngioGenex is a publicly traded company, trading on the OTC exchange with the ticker symbol AGGX. Our filings with the Securities and Exchange Commission(SEC) can be found here.